About Olema Oncology
Olema Oncology (Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on transforming the metastatic breast cancer treatment paradigm and improving outcomes for patients with breast cancer and beyond. Its lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two Phase 3 clinical trials, with a second pipeline asset OP-3136, a KAT6 inhibitor, in Phase 1.
Company details
Funding
Total raised
$389M
Last stage
Public
Investors
Founders
Peter Kushner
Co-founder and Chief Scientific Officer of Olema Oncology, a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer.
Cyrus L. Harmon
Co-founder of Olema Oncology (formerly Olema Pharmaceuticals).
Sean P. Bohen
President and Chief Executive Officer of Olema Oncology; previously an executive at Genentech and AstraZeneca.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.